by H.S. AyoubBioHealthInvestor.com Monday looks to be a great day for biotech stocks as this past weekend saw a flurry of news releases announcing clinical trial data and results at the 48th annual meeting…
GlaxoSmithKline (GSK) is a pharmaceutical stock which has outperformed the S&P with less volatility, and which may also benefit if the U.S. Dollar continues to weaken against European currencies. And as a kicker, Glaxo…
From BioHealth Investor by Adam Rubenstein NeoVista, Inc. (Fremont, CA), an ophthalmic device company focused on the treatment of age-related macular degeneration, has raised $41M in Series C funding. Essex Woodlands Health Ventures led…
From BioHealth Investor by H.S. AyoubBioHealthInvestor.com Shares of Vanda Pharmaceuticals (VNDA) look to open much higher on Thursday as the company announced early that its antipsychotic drug iloperidone met the primary endpoint in a…
From BioHealth Investor by Mark S. Senak As the lame duck Senate gets ready to waddle off to their place in history, they have moved to pass S. 3546 – a bill that would…
Stock Tickers: BSX, JNJ, ANPI, SRDX, CONR, BMY, SNY, ABT, MDT The FDA review of stents should not change the current practice, and that is for drug coated and uncoated stents. If it does…
Stocks: (MRK)(BSX)(JNJ)(PFE) Yet another investigation of the health affect of stents. Where will it end? The FDA is bringing in outside experts to get their opinions on the dangers of drug coated stents.Boston Scientific…
From BioHealth Investor I recommended Halozyme Therapeutics (HTI) in August (and mentioned it again last week that I was holding it in my biotech portfolio) as a nano-cap biotech. What I liked best about…
Comscore has released data that say that 33 million people researched presciption medications on the internet in Q3. That is up 18% from the same quarter last year. More important for Big Pharma, 31%…
Comscore has released data that say that 33 million people researched presciption medications on the internet in Q3. That is up 18% from the same quarter last year. More important for Big Pharma, 31%…
Vioxx lawsuit could drag on for years, even a decade. But, Merck is looking ahead. It confirmed 2006 guidance and said that 2007 would be in the range Wall St. hopes for. The company…
From BioHealth Investor BayBio, Northern California’a leading biotechnology industry organization, published its landmark study BayBio: IMPATCT 2007. What does Northern California know about the state of biotechnology? That region alone is home to 1/3…
By Chad Brand of Peridot Capitalist Not too long ago I wrote about pharmaceutical giant Pfizer (PFE) and how it trades at a seemingly steep discount to its peer group, and boasts a 3.9%…
On tonight’s MAD MONEY show on CNBC, Cramer reviewed what the state of the stent market will be. There is a meeting Thursday at the FDA where the FDA is going to make a…
Somaxon Pharmaceuticals (SOMX-NASDAQ) has announced essentially failed results from the company’s Phase 2/3 clinical trial evaluating 20 mg and 40 mg of oral nalmefene hydrochloride, an opiate antagonist, in patients with a diagnosis of…